People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2012 |
| Dicerna Pharmaceuticals Inc | — | Biotechnology | Series C | $118.9M | $2.5B | 2010 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2012 |
| Talphera, Inc. | — | Pharmaceuticals | Series B | $97.4M | $74.2M | 2010 |
| Apic Bio, Inc. | — | Biotechnology | Series C | $55.4M | $196.0M | 2021 |
| Body & Mind Inc. | — | Other | Series A | $27.9M | $915K | 2020 |
| Rythera Therapeutics Inc. | — | Biotechnology | Seed | $1.3M | $21.8M | 2022 |
Stephen Hoffman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Hoffman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Ali Behbahani | 1 | 17 |
| David Hirsch | 1 | 16 |
| LEON CHEN | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| William Clark | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Mark Wan | 1 | 10 |
| Michael Higgins | 1 | 9 |
| Jason Dinges | 1 | 8 |
| Simeon George | 1 | 8 |
| Jonathan MacQuitty | 1 | 7 |
| Dong Shim | 1 | 7 |
| John Freund | 1 | 7 |
| Howard Rosen | 1 | 5 |
| Brian K. Halak | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Gino Santini | 1 | 5 |
| Michael Heffernan | 1 | 5 |
| Dong H. Shim | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.